The magnitude of the immune response to a DNA vaccine depends on three criteria-the optimized vector design, the use of a suitable adjuvant and the successful delivery and subsequent expression of the plasmid in the target tissue. In vivo electroporation (EP) has proved to be particularly effective in efficiently delivering DNA immunogens to the muscle and the skin, and indeed several devices have entered into human clinical trials. Here, we report on a novel concept of DNA delivery to the dermal tissue using a minimally invasive EP device, which is powered using low-voltage parameters. We show that this prototype device containing a novel 4Â4-electrode array results in robust and reproducible transfection of dermal tissue and subsequent antigen expression at the injection site. Using DNA encoding for NP and M2e influenza antigens, we further show induction of potent cellular responses in a mouse model as measured by antigen-specific T-cell ELISpot assays. Importantly, 100% of the immunized animals were protected when challenged with VN/1203/04 (H5N1) strain of influenza. We have also extended our findings to a guinea-pig model and demonstrated induction of HI titers greater than 1:40 against a pandemic novel H1N1 virus showing proof of concept efficacy for DNA delivery with the prototype device in a broad spectrum of species and using multiple antigens. Finally, we were able to generate protective HI titers in macaques against the same novel H1N1 strain. Our results suggest that the minimally invasive dermal device may offer a safe, tolerable and efficient method to administer DNA vaccinations in a prophylactic setting, and thus potentially represents an important new option for improved DNA vaccine delivery in vivo.
INTRODUCTION
A major obstacle to effective vaccination through antigenic plasmids is the need of the DNA vaccine to be delivered intracellularly. The delivery of naked DNA through a standard intramuscular (IM) injection is notoriously inefficient outside of rodent models. This has lead to an inability to achieve robust immune responses in large mammals and humans. 1, 2 Several strategies have been developed to enhance the expression of DNA-based vaccines, such as codon optimization, RNA optimization, addition leader sequences and the development of optimized consensus sequences. [3] [4] [5] [6] [7] These optimization strategies can lead to improved, cross-reactive immune responses. 8, 9 The addition of co-delivered gene-based molecular adjuvants is another area in which an augmentation of resulting immune responses frequently occurs. Despite the improvements in vector design and the use of molecular adjuvants, there is still a clear requirement for an efficient method of administration of DNA vaccines that results in high-level expression of the plasmid in the desired cell type of the desired tissue, most commonly, muscle, tumor or skin.
Drug delivery to dermal tissue (intradermal, ID) is an attractive method in a clinical setting for a number of reasons. The skin is the largest organ of the human body, the most accessible, most easily monitored, as well as highly immunocompetent. 10, 11 However, the impervious, function of the skin as a barrier has been a major obstacle in efficient transdermal drug delivery.
Human skin extends to approximately 2 m 2 in area and is 2.5 mm thick on average, thus, making it the largest organ of the human body. 11 Conventionally, the skin has two broad tissue types, the epidermis and the dermis. The epidermis is a continually keratinizing stratified epithelium. The outermost layer of skin is the stratum corneum (SC) and functions as the primary barrier for skin. The Stratum corneum is a 15-30 cell thick layer of nonviable, but biochemically active corneocytes. The other three strata of the epidermis (S. granulosum, S. spinosum and S. basale) all contain ketatinocytes at different stages of differentiation as well as the immune Langerhans cells and dermal dendritic cells. [11] [12] [13] Both physical and chemical methods for transdermal drug delivery and gene delivery have been detailed by groups worldwide. Iontophoresis, lipid delivery and gene gun are such examples. [14] [15] [16] A physical method to temporarily increase skin permeability is electroporation (EP). It involves the application of brief electrical pulses that result in the creation of aqueous pathways within the lipid bilayer membranes of mammalian cells. This allows the passage of large molecules, including DNA, over the cell membrane, which would otherwise be less permeable. As such, EP increases the uptake, as well as the extent to which drugs and DNA are delivered to their target tissue. [17] [18] [19] [20] [21] Although the precise mechanism by which EP functions has not been elucidated, a proposed theoretical model involves a poration event because of the destabilization of the membrane, followed by the electrophoretic movement of charged molecules into the cell. For EP to occur the formation of pores requires that a threshold energy be achieved and the movement produced by the electrophoretic effect depends on both the electric field and the pulse length.
In the case of DNA vaccines, EP has been shown to quantitatively enhance immune responses, increase the breadth of those immune responses as well as improve the efficiency of dose. 21 The many advantages of skin delivery, most notably the presence of a variety of immune relevant cells, easy clinical accessibility as an immunization target organ and the minimal depth of delivery (minimally invasive) prompted us to investigate the possibility of developing a dermal EP device that would be considered tolerable, user-friendly and easily amenable to mass production, while continuing to achieve hightransfection rates, resulting in robust immune responses. We previously reported on a subcutaneous DNA delivery device with a penetration depth of 3 mm (CELLECTRA-3P) 22 and IM DNA delivery devices Medpulser, 23 ELGEN 24 and CELLECTRA-5P 25 devices. Each of these devices has been produced under current good manufacturing practice and has entered human clinical trials with therapeutic and/or prophylactic DNA vaccines. These devices cover injection depths of 3-25 mm, typically suited for subcutaneous and/or IM vaccine delivery using distinct EP array configurations.
Hirao et al. 22 demonstrated that ID/subcutaneous EP resulted in higher cellular and humoral responses to an human immunodeficiency virus vaccine in nonhuman primates compared with ID/subcutaneous injection alone. In Laddy et al., 26 both routes of EP (IM and ID) offered protection in nonhuman primates challenged with a highly pathogenic avian influenza virus. Interestingly, better protection from challenge, as shown by decreased viral loads, was obtained using ID immunization.
Here we investigate the immune responses elicited by a shallower DNA delivery (ID) using a novel 4Â4-minimally invasive needle array. This ID device differs from other EP devices in that the electrodes are minimally invasive (scratch the skin surface and do not penetrate the skin) and operate at significantly lower voltages (15 V) compared with some of the other devices that routinely operate at 50-100 V (nominal voltage), or under constant current conditions. The distinctive electrode configuration is also designed to achieve better threshold electric fields over a wider area at lower applied voltages. Specifically, the work here details the effective uptake and expression of DNA plasmids resulting in robust immune responses, both humoral and cellular, into the skin by the novel EP procedure. We believe that our prototype device targeting predominantly the skin, using low-voltage parameters to achieve both high and consistent levels of immunogenicity, offers an attractive option as an efficient method for delivering DNA vaccinations in a clinical setting.
RESULTS

Prototype development of a novel concept minimally invasive EP device
In a bid to potentially improve on EP devices in current use and to enhance delivery to the immunologically important skin tissue, we designed a minimally invasive electrode device (MID). During the early prototype development stage, we homed in on a 4Â4-electrode array pattern for the MID dermal device to provide an optimal balance between electrode spacing, coverage of target area, anticipated injection volume for downstream vaccine applications, pulse length and voltage parameters. We conducted numerous empirical experiments by varying these parameters to optimize the gene expression and the immunogenicity to arrive at the selected electrode configuration and firing pattern.
Ultimately, the new EP applicator consists of gold-plated stainless steel needle electrodes with trocar grinds at 1.5 mm spacing in a 4Â4-array pattern (Figures 1a and c) . Alternating rows of four electrodes are fired with reverse polarity that is, positive then negative. The electrodes are captured in electrical sockets within the plastic handle, allowing each electrode to be addressed individually for alternative firing patterns. The device is designed to make contact with the surface of the skin only and not directly penetrate the tissue. The prototype device was built with an attachment cord for linkage to a pulse generator (Figure 1b) , ELGEN 1000. 23 Electroporation using a MID results in robust reporter gene transfection To address methods for improving delivery, we investigated the lower limits of voltage parameters required for successful transfection and immune responses using this new minimally invasive needle electrode device (MID). Separate skin sites on the flank of a guinea pig were injected with 50 ml of 1 mg ml À1 green fluorescent protein (GFP) plasmid and immediately pulsed using the MID set at 15 V (Figure 2a ). Robust and reproducible GFP transfections were visible at 8 h following treatment and peaked at 3 days. Minimal or no GFP transfection was detectible following GFP plasmid injection alone (data not shown). Although a range of electrical parameters and voltages resulted in GFP transfection, pulses at 15 V were more reproducible (data not shown). Reproducibility was quantified and Figure 1 Prototype development of a novel concept minimally invasive electroporation device. From concept drawings to working prototype. (a) CAD drawing of a prototype minimally invasive device (MID) consisting of trocar gold-coated needle electrodes at I.5-mm spacing in a 4Â4-array pattern. (b) The array is attached to the handle of the device and connected directly into the pulse generator (Elgen 1000) through a wired connector. EP can be triggered either through activation of a foot pedal or a trigger button on the screen. (c) The built-functioning prototype.
Prototype development of a novel EP device KE Broderick et al assessed by positive pixel count following fluorescence microscopy at standardized conditions. The most consistent pixel count numbers within a defined area were obtained at the 15-V parameters. Actual GFP transfection patterns appeared as distinct 'islands' around the contact point with each electrode (Figure 2b ). We also carried out dose-response experiments using DNA at doses ranging from 2 to 0.1 mg ml À1 (Figure 2c ). The most robust transfection was observed at 2 mg ml À1 and the reduction in dosage corresponded with a reduction in visible transfection.
Histological analysis demonstrates transfection in the upper layers of the epidermis To address the effect of EP by the MID on a cellular level, histological analysis was carried out. Sites on a guinea pig were injected with 50 ml of 1 mg ml À1 GFP plasmid and immediately pulsed using the MID. Biopsy samples were removed 3 days post treatment, then were fixed, paraffin sectioned and were hematoxylin and eosin stained ( Figure 3a ). Pathological analysis revealed no associated tissue damage following EP with the MID. High-powered microscopy revealed that the majority of GFP transfection occurred in the S. granulosum cell layer of the epidermis (Figure 3b ). GFP positive cells were also detected in the S. basale. In contrast, only a few GFP positive cells were detected in the biopsy sample that received GFP plasmid injection alone. This was in direct contrast to the robust signal observed in the biopsy sample from the tissue that had received EP. A visual estimation of enhancement of expression is in excess of 100-1000-fold based on number of GFP positive cells relative to DNA alone and is consistent with previous reports of enhancement of expression achieved with other EP devices. [18] [19] [20] Minimally invasive EP results in a positive transfection in a wide spectrum of species To ensure that the robust transfection was not a guinea pig-specific phenomenon, we carried out GFP localization in a wide range of species. Skin sites on mice, rabbits, rats and pigs were injected with 50 ml (30 ml in mice) of 1 mg ml À1 GFP plasmid and immediately pulsed using MID. All species demonstrated robust dermal GFP transfection following EP with MID or no transfection detected following GFP plasmid injection alone ( Figure 4) . In all the species, strong GFP positivity was detected in all the electroporated skin samples. However, only the rabbit samples demonstrated the distinctive 'island' pattern that was observed in the guinea pig samples ( Figure 2 ). The GFP localization on the rat, mouse and pig's skin appeared more diffused. The actual transfected area was similar among rats, rabbits and pigs (approximately 4 mm 2 ) as this is a function of the injection bubble size. The transfected area on the mouse skin was slightly smaller because of the smaller injection volume. On the mouse panel, the entire skin of the mouse is shown so that relative size can be appreciated. GFP positive cells were detected only on the surface of the skin in the rat, rabbit and pig samples. No GFP signal was observed on the underside of these samples. Only in the mouse skins, did we observe a positive GFP signal on the underside. However, this appears to be related to the thin structure of the mouse skin. This data suggests that MID can efficiently transfer plasmid to the skin across both the small and large animal models.
Electroporation with the MID results in robust cellular responses as well as providing 100% protection against the lethal challenge in mice Having demonstrated enhanced plasmid delivery over no EP and localization to the dermis, we next sought to assess recruitment of the immune system components following DNA delivery by MID to elicit disease-relevant immune responses. We assessed DNA plasmidmediated cellular and humoral responses using influenza antigens as target antigens.
Our initial studies used mice as a model system because of the broad availability of reagents to conduct assessment of cellular responses through ELISpot assays. Mice were immunized with DNA encoding for NP and M2 influenza antigens: prime 30+30 mg, week 0; boost 30+30 mg, week 3; boost 100+100 mg, week 10. Matched NP antigen from A/H1N1/Puerto Rico/39 strain and matched M2 antigen from A/H1N1/New Caledonia/99 strain were optimized, synthesized and then cloned into the backbone of a mammalian expression vector, pMB76.5, which has been used in previous human clinical trials. The NP and M2e antigens were chosen to assess predominantly cellular immunity. These proteins are not able to induce neutralizing antibody responses. Groups of mice were electroporated either with the minimally invasive dermal device or with the ELGEN 1000 IM device. Induction of potent cellular and humoral responses in the mouse model as measured by antigen specific T-cell ELISPot assays and antibody titers were observed in all mice. Antigen-specific cytotoxic T-lymphocytes responses were 200±57.9 SFU per 10 6 splenocytes against NP for MID and 85 ± 36.3 SFU per 10 6 splenocytes against NP for IM (Figure 5a ). Those animals electroporated ID showed higher titers and cellular responses that were statistically significant (Po0.05).
In a bid to determine whether the induced immune responses were capable of impacting infection, mice were challenged with a lethal dose of influenza A/H5N1/Vietnam/1203/04 through intranasal inoculation (Figure 5b ). The VN/1203/04 (H5N1) strain of influenza is known to cause rapid morbidity and mortality. Although 100% of the naïve mice succumbed to infection by day 11, 100% of the mice immunized with the MID were protected against both morbidity and mortality through day 15 (end of the experiment). Similarly, at day 15, 90% of the IM immunized positive control animals survived.
Electroporation employing the MID results in humoral immunogenicity and protective HI titers in guinea pigs
We next sought to assess induction of humoral immunity after DNA immunization with the MID. It is difficult to target the dermis in mice because of the extremely thin skin structure and the close proximity of underlying muscle. For this reason, often immune responses induced in mice are a combination of skin and muscle. We therefore tested the device in larger animal model-guinea pigs, which have a betterdefined skin structure. Guinea pigs were immunized with a variant of a previously described consensus SynCon influenza vaccine by ID EP by MID. 26, 27 The previous studies were conducted with a vaccine targeting avian influenza A/H5N1. In this study, we targeted the induction of protective humoral responses against influenza A/H1N1 strains, including the novel influenza A/Mexico/09/H1N1 (2009). Having failed to achieve appreciable expression of plasmid through IM/ID injection alone (without EP) at these doses (GFP data above; and previous immunogenicity studies with DNA alone, [17] [18] [19] [20] [21] [22] we focused our experiments instead on determining the level of humoral immune responses induced by MID delivery. Animals were vaccinated with a combination of plasmids targeting the H1N1 strains (100 mg per plasmid) containing pGX2005 (SynCon vaccine construct that encodes a consensus sequence of hemagglutinin (HA) from H1N1 viruses) 27 and pGX2009 (SynCon vaccine construct that encodes a consensus HA sequence derived from the swine origin influenza A/H1N1 (2009) strains in a volume of 50 ml diluted in 1Âphosphate-buffered saline (PBS). At 2 weeks following two immunizations, each animal developed robust HA-inhibition (HAI) titers (average (1152±784) and significantly over 1:40 against the pandemic H1N1/Mexico/2009 strain (Figure 6a ). Titers greater than 1:40 are considered to be protective in the influenza model in a number of species. In parallel, we found that the antibody titers generated from MID in guinea pigs was comparable to those generated from IM-EP (data not shown) using the ELGEN-1000 device. Electroporation with the MID results in detectible HI titers greater than 1:40 in macaques We next demonstrated that DNA vaccine delivery through MID also resulted in protective humoral responses in nonhuman primates. As performed with the guinea pigs, macaques were vaccinated with a plasmid combination (100 mg per plasmid) containing pGX2005 and pGX2009 in a volume of 50 ml by ID (MID) EP. Following two immunizations, all four animals developed strong HAI titers over 1:40 (average 340 ± 199) against the H1N1/Mexico/ 2009 strain when immunized ID with MID (Figure 6b ). In terms of reference, the same plasmids delivered through IM injection followed by EP with the ELGEN-1000 device also led to strong HI titers, that is, over 1:40 in all the vaccinated animals (average 280 ± 207) at 2 weeks after the second immunization. In this study, both the delivery routes yielded strong humoral responses and the titers developed using the MID-ID and the ELGEN-IM delivery were not statistically different (P¼0.4).
DISCUSSION
Although DNA vaccines currently offer a number of advantages over conventional vaccines, they have suffered from a lack of efficacy when tested in larger mammal models, including humans. In vivo EP has offered an effective physical delivery method, which can improve both the expression and immunogenicity of DNA vaccines by 100-1000-fold. 21 Although multiple EP protocols are currently being evaluated in the clinic, primarily with the objective of demonstrating immunogenicity and efficacy, recent attention has focused on improving the tolerability from the patient's perspective. New delivery devices expand treatment and vaccine options and may result in a novel induction of immunity. The current work details the prototype development of a novel, dermal EP device (Figure 1 ) that is minimally invasive, and as a result is likely to be highly tolerable, while still maintaining efficacy and giving reproducible results. The MID was developed with individually addressable electrodes to allow us to test multiple-firing patterns and different electric fields. We note that although other EP devices have used different firing patterns to generate optimally efficient electric fields in the target tissue based on their electrode configuration we found the reverse polarity firing pattern to be optimal for MID.
The results detailed here demonstrate that minimally invasive EP provides an efficient approach for dermal-targeted gene expression. We tested approaches to dermal gene delivery (ID injection followed by surface EP) by applying them to the transfer and expression of a GFP reporter gene plasmid and antigenic influenza plasmids.
Our design efforts were guided in part, in an attempt to improve on the EP associated tolerability-a function of both depth of insertion and electric field strengths used to achieve optimal DNA delivery. Specifically, we reduced the voltage and pulse lengths of our electrical parameters. Using GFP localization, we were able to observe transfection of the epidermal tissue over a wide spectrum of voltage parameters, ranging from the routinely used 100 V down to 1 V (data not shown). Interestingly GFP transfection at lower voltage parameters (15 V) appeared more reproducible and robust in comparison with the 50-100 V parameters with this device. It is likely that the shallower skin structure, different conductive properties of skin in relative to the subcutaneous tissue or muscle as well as the closer spacing of the needle electrodes in relative to other IM-EP devices can promote the induction of optimal field strengths for efficient DNA delivery and uptake at significantly lower voltages. GFP transfection appeared as distinct 'islands' around the contact point with the electrode, suggesting localization of expression around areas of optimal field strength ( Figure 2) . We investigated the reproducibility of expression as measured by GFP reporter genes. We found that treatment-site to treatment-site reproducibility was significantly improved once the operator was trained in administering ID injections (Mantoux) and using this device. We also demonstrated a dose-response effect related to the actual dosage of the plasmid administered to the skin. The most robust GFP transfection was observed at 2 mg ml À1 (50 ml volume; 100 mg) with the observed transfection decreasing with DNA dose.
Histological analysis of biopsy samples taken from a guinea pig skin, which is electroporated with this device, demonstrated no sign of tissue damage 3 days post treatment (Figure 3a) . We believe that the mechanism of action pertaining to this device is through a localized high-current density only in the depth of a few cell layers, resulting in exceptionally shallow transfection. This is supported by the histological analysis, which showed that the majority of GFP positive cells were present in the upper layers of the epithelium (Figure 3b) . Significantly, there were transfected cells in the S. basale, which could contribute to long-term expression in this tissue. Signs of inflammation were observed at the treatment site following EP at voltage parameters greater than 50 V. Ultimately, we optimized immunogenicity (higher) and inflammation (lower) in arriving at 15 V for the operating parameters for the MID. Studies are currently ongoing to directly identify which dermal cells are being transfected by this approach.
Although the guinea pig is an established dermatological animal model, the benefit of minimally invasive EP would be limited if the results did not translate into other species. As such, we also tested this device in mice, rats, rabbits, pigs and nonhuman primates (Figures 4,  5 and 6 ). Localization data were reproduced in all the species (Figure 4) . We believe that the successful results found in this study in several species, including primates, are likely to translate well into humans.
We were interested in determining whether DNA delivery with the MID was able to induce meaningful cellular responses in a relevant disease model. Historically, IM EP has been considered necessary to generate functional T-cell responses and it was considered difficult to generate cellular responses from ID vaccination protocols. We chose to study the induction of cellular responses based on the influenza M2e and NP proteins. A number of previous studies have reported on the role of cellular immunity in protecting against morbidity and mortality, resulting from influenza infection. 26, 27 Many of these reports have also studied M2e and NP proteins. In our study, mirroring the antibody responses (discussed below), we found that the MID generated higher cellular responses in mice than those observed with an IM device (ELGEN 1000) that uses the same pulse generator, but an IM array configuration with an previously optimized EP parameters. 24 The ID-administered pNP produced responses of significant magnitude against the administered antigen, whereas the IM-administered pNP group was detectible but lower. Interestingly, this is the opposite of the work detailed in Laddy et al. 26 in which the cellular immunogenicity in macaques was analyzed following IM and ID-EP immunization with an influenza DNA vaccine with a different EP device (CELLECTRA device) and different electrode configurations. The macaques NP IM ELISpot responses in the Laddy et al. study were also clearly higher than the responses we detected in mice used in our study, pointing towards a species difference as well as likely because of the differences in the optimized plasmids, target tissues and EP systems used in the study. In the paper by Laddy et al., an ID device that targeted both the dermal and subcutaneous layer (3 mm deep needles) was used and achieved both strong neutralizing antibodies and HAI titer responses that also subsequently led to protection in a challenge model. Although the significant differences in the approaches between the two studies makes a direct comparison between them difficult, we are nevertheless encouraged by the fact that the cellular immune responses achieved by the MID were significant and clinically relevant in that they conferred 100% protection to the vaccinated animals against a lethal challenge of influenza H5N1.
However, this does raise an important point that all EP devices may not operate the in same manner and the immune responses developed may be modulated depending on the DNA plasmid constructs, choice of target tissue, insertion depth and choice of device (array configuration and pulse parameters) used for delivery. Thus, depending on the clinical/immunological target responses desired, several parameters need to be co-optimized for effective vaccine development.
The induction of strong humoral immune responses at levels significantly greater than those commonly associated with protection (HI titers 41:40) in guinea pigs (Figure 6a ) and macaques ( Figure 6b ) vaccinated with our MID device following two immunizations demonstrated that the DNA is transcribed and translated into a protein antigen-bearing functionally relevant epitopes and that in vivo EP through MID is an efficient means of delivering such vaccines. In the Laddy et al. publication, we demonstrated that although both routes of EP (IM and ID) offered protection in nonhuman primates, challenged with a highly pathogenic avian influenza virus, 26 better protection from challenge, as shown by decreased viral loads, was obtained using ID immunization. This study with the MID device and influenza antigens further confirms that dermal delivery through EP can lead to significant humoral immune responses.
The DNA vaccine injection in this procedure is through a standard ID (Mantoux) injection. Because of the shallow injection and EP procedure, the ID route offered by MID would also likely further improve on the tolerability of the important EP platform and provide a new option for targeting immunization in the skin. The data supports the notion that the cellular and humoral responses induced can impact disease in animal-model systems. Clearly, further study of this immunization system and its examination in the clinic will be important. MID may prove to be effective for DNA delivery in other disease targets in which the induction of NAb and/or binding Ab responses is thought to have a role.
Gene transfer by minimally invasive EP has several advantages over currently available EP devices. We believe that the use of nonpenetrating needle electrodes and lower-voltage parameters encompassed in this device concept will further improve tolerability of this platform. It allows for simple delivery to the skin, which can serve to expand applications for DNA delivery in humans. It also facilitates much more detailed control of the pulse pattern to allow delivery of more complex formulations and antigen mixtures. The array also allows us to contemplate delivery of multiple antigens at adjacent but spatially distinct sites to mitigate potential concerns of antigenic interference. 28, 29 In addition, by combining with new formulations it allows for an effective delivery of much lower doses and dose volumes that may have a bearing on the ultimate use of the vaccines in the field on licensure. Furthermore, the MID device extends the range of immunizations into both older and younger populations, as well as in other specific disease situations in which the muscle mass may be an issue for effective delivery. Many research studies suggest that the skin can have advantages for induction of an immune response. The humoral and cellular responses achieved through MID are particularly encouraging and supportive in this regard.
MATERIALS AND METHODS
Minimally invasive device design
Electrode arrays consisting of a 4Â4-gold-plated trocar needle of 0.0175-inch diameter at a 1.5-mm spacing were constructed to be used in conjunction either with the ELGEN1000 (Inovio Pharmaceuticals, San Diego, CA, USA) pulse generator or with a battery-powered low-voltage circuit.
Plasmid preparation
The gWiz GFP plasmid were purchased from Aldevron (Fargo, ND, USA). The NP plasmid encodes the full-length NP derived from A/Puerto Rico/8 (H1N1) strain of influenza. The M2 plasmid encodes the full-length M2 derived from A/New Caledonia/99 (H1N1) strain of influenza. The construct had the nucleus-targeting signals mutated and was optimized and synthesized by GeneArt (Regensburg, Germany). All plasmids were diluted in 1ÂPBS before injection. SynCon influenza vaccine plasmid cocktail (100 mg per plasmid) containing pGX2005 (SynCon vaccine construct that encodes a consensus sequence of H1HA) and pGX2009 (SynCon vaccine construct that encodes a consensus sequence of swine H1HA) were diluted in 1ÂPBS before injection. The SynCon plasmids were developed and manufactured by Inovio.
Animals
Female Hartley guinea pigs (strain code 051), female New Zealand rabbits and female Balb C mice were purchased from Charles River Laboratories (Wilmington, MA, USA). Female Wistar rats were purchased from Charles River Laboratories. Female Yorkshire pigs were purchased from S & S Farms (Ramona, CA, USA). Guinea pigs (six animals per group), rats, rabbits and mice (10 animals per group) were housed at BioQuant (San Diego, CA, USA).
Macaques (four animals per group) (Macaca mulatta) were individually housed at BIOQUAL Inc. (Rockville, MD, USA), with ad libitum access to food and water. Macaques were allowed to acclimate for at least 30 days in quarantine before experimentation. All animals were housed and handled according to the standards of the Institutional Animal Care and Use Committee.
Preparation of animals
The GFP reporter results observed on the Hartley guinea pigs after hair removal was the same as that observed on the IAF (Institute Armand Frappier) hairless guinea pigs in previous experiments. As hair removal appeared to have no effect on the resulting transfection and because of cost considerations, we chose to carry out the rest of the study in the Hartley animals.
Hartley guinea pigs were shaved and stubble was removed by dilapatory cream (Veet, Reckitt Benckiser, Parsippany, NJ, USA) 24 h before treatment. Mice, rats, rabbits, pigs and macaques were shaved before treatment.
DNA injections
Macaques were sedated with injected ketamine. All other animals were sedated with inhaled isoflurane. All animals were injected ID (Mantoux method (needle parallel to skin)-29-gauge insulin needle) with 50 ml of 1ÂPBS containing the desired dose of plasmid. Mice were injected IM into the quadriceps with 50 ml of 1ÂPBS containing the desired dose of plasmid. Empty vector was added to maintain equal DNA amounts for each group. For the guinea-pig study, animals were vaccinated three times at 3 weeks apart with 100 mg plasmid at each immunization. The macaques were vaccinated three times at 4 weeks apart with 100 mg plasmid at each immunization.
Dermal device EP
Immediately following injection of DNA, the dermal device was applied to the site of dermal injection. The array was 'wiggled' at the injection site to ensure good contact and electrotransfer was achieved through pulse generation either from the ELGEN 1000 or a low-voltage battery circuit. The parameters used were three 15-V pulses of 100 ms duration.
Muscle EP
Immediately following IM injection, EP was performed by inserting 27-gauge, 2-needle array with a 4-mm electrode spacing (Inovio Pharmaceuticals) at the site of the injected muscle. Two 125 V cm À1 pulses lasting 60 ms each were delivered using the ELGEN 1000.
Imaging of skin
Skin or biopsy samples were removed post-mortem from animals after termination and stored on ice until imaged under an OV 100 imaging microscope (Anti Cancer Inc., San Diego, CA, USA) at 480 nm.
Histopathology
Skin or biopsy samples were removed post-mortem from animals after termination and immediately preserved in 10% neutral-buffered formalin and sent to Pacific Pathology, San Diego, CA, USA for processing and histopathological analysis. Appropriate tissues were trimmed, processed, embedded in paraffin, sectioned at approximately 5 mm and stained with hematoxylin and eosin. The resulting slides were examined by a Board-certified pathologist. The sections were visualized using a Zeiss Axioplan (Thornwood, NJ, USA) microscope with a Â20 objective at the Burnham Institute, San Diego, CA, USA.
ELISpot assay
At 2 weeks after the immunization, splenocytes from each group of mice were isolated and tested individually. Single-cell suspensions were cleared of red blood cells using RBC lysis buffer (eBioscience, San Diego, CA, USA). The ELISPOT assay kit was purchased from R&D Systems (Minneapolis, MN, USA). The 96-well ELISPOT plates (Millipore, Billerica, MA, USA) were coated with anti-mouse interferon-g monoclonal antibody. After overnight incubation at 4 1C, the wells were washed and blocked with blocking buffer according to the protocol from R&D Systems. Pooled splenocytes from each group were added to the wells and incubated with 1 mg ml À1 single peptide NP147 (TYQRTRALV; Biosynthesis Inc., Lewisville, TX, USA) for 48 h. The plates were then washed and developed following the protocol described by the manufacturer. The spots were counted and analyzed by Cellular Technology (Shaker Heights, OH, USA). Results are shown as spot-forming units per million splenocytes.
Intranasal influenza challenge
Balb/c mice in groups of 10 were immunized with NP and M2 plasmids on weeks 0, 3 and 6. Mice were immunized: prime 30+30 mg week 0; boost 30+30 mg, week 3; boost 100+100 mg, week 10. Mice were then rested for 5 weeks. At week 15, Flu-challenge experiments were conducted using BSL IV protocols at The National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada according to ethical guidelines of their Ethical Committee. A 100ÂLD50 dose of H5N1 A/Vietnam/1203/04 strain was used for nasal challenge administered under anesthetic condition. Mice were then monitored for survival and body weight every day for 21 days following challenge.
HAI assays
Animals were bled and sera samples immediately stored on dry ice before being shipped to BIOQUAL for processing. Sera were treated with receptor-destroying enzyme by diluting one part serum with three parts enzyme and were incubated overnight at 37 1C water bath. The enzyme was inactivated by 30-min incubation at 56 1C, followed by the addition of six parts PBS for a final dilution of 1/10. HAI assays were performed in V-bottomed 96-well microtiter plates, using four HA units of virus and 1% red blood cells. Virus stock (H1N1/Mexico/2009 strain) used for the HAI assays was obtained from the influenza branch of the CDC (Center for Disease Control).
Statistical analysis
Data presented as the mean ± s.d. were calculated from triplicate wells of pooled lymphocytes from each experimental group. Where appropriate, the statistical difference between immunization groups was assessed using a two-tailed, paired Student's t-test that yielded a specific P-value for each experimental group. Comparisons between samples with a P-value o0.05 were considered to be statistically different and therefore significant.
